Miyako Satouchi
Kobe University
185 Papers
1.2K Citations
Miyako Satouchi is an academic researcher from Kobe University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 38, co-authored 164 publications.
Chat about Author
Papers
Effect of Second-generation vs Third-generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III Non-Small-Cell Lung Cancer: 10-Year Follow-up of a WJTOG0105 Phase 3 Randomized Clinical Trial.
Yoshitaka Zenke,Masahiro Tsuboi,Yasutaka Chiba,Kayoko Tsujino,Miyako Satouchi,Kenji Sawa,Junichi Shimizu,Haruko Daga,Daichi Fujimoto,Masahide Mori,Takuya Aoki,Toshiyuki Sawa,Shota Omori,Hideo Saka,Yasuo Iwamoto,Motoyasu Okuno,Tomonori Hirashima,Kosuke Kashiwabara,Motoko Tachihara,Nobuyuki Ymamoto,Kazuhiko Nakagawa +20 more
TL;DR: In this article, the authors evaluated the long-term outcomes and cumulative incidences of toxic effects associated with chemoradiotherapy (CRT) for patients with stage III non-small-cell lung cancer.
7
LBA55 WJOG @Be study: A phase II study of atezolizumab (atez) with bevacizumab (bev) for non-squamous (sq) non-small cell lung cancer (NSCLC) with high PD-L1 expression
Takashi Seto,Kaname Nosaki,Mototsugu Shimokawa,Ryo Toyozawa,Shunichi Sugawara,Hidetoshi Hayashi,Haruyasu Murakami,Terufumi Kato,Seiji Niho,Hideo Saka,Masahide Oki,Hiroshige Yoshioka,Isamu Okamoto,Haruko Daga,Koichi Azuma,Hiroshi Tanaka,Kazumi Nishino,Miyako Satouchi,Nobuyuki Yamamoto,Kazuhiko Nakagawa +19 more
7
Phase 1 study of ombrabulin in combination with docetaxel and cisplatin in Japanese patients with advanced solid tumors.
Makoto Nishio,Miyako Satouchi,Atsushi Horiike,Yoshitsugu Horio,Yoshinori Sunaga,Evelyne Ecstein-Fraisse,Toyoaki Hida +6 more
TL;DR: A combination regimen of ombrabulin with cisplatin and docetaxel was not feasible for Japanese patients owing to the occurrence of hematological and non-hematological DLTs at the initial dose level.
7
A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer
Yoshihiro Hattori,Yuko Kono,Shoichi Itoh,Takako Inoue,Yoshiko Urata,Yoshitaka Kawa,Rie Tohnai,Toru Kumagai,Kazumi Nishino,Ryuji Uozumi,Satoshi Morita,Shunichi Negoro,Fumio Imamura,Miyako Satouchi +13 more
TL;DR: Nab-paclitaxel plus cisplatin was well tolerated and associated with encouraging response outcomes in chemotherapy-naïve patients with advanced NSCLC, and the primary endpoint was the objective response rate.
A phase III study comparing amrubicin and cisplatin (AP) with irinotecan and cisplatin (IP) for the treatment of extended-stage small cell lung cancer (ED-SCLC): JCOG0509.
Yoshikazu Kotani,Miyako Satouchi,Masahiko Ando,Kazuhiko Nakagawa,Nobuyuki Yamamoto,Yukito Ichinose,Yuichiro Ohe,Makoto Nishio,Toyoaki Hida,Koji Takeda,Tatsuo Kimura,Koichi Minato,Akira Yokoyama,Shinji Atagi,Taro Shibata,Haruhiko Fukuda,Tomohide Tamura,Nagahiro Saijo +17 more
TL;DR: A phase III trial comparing AP with IP, which has shown promising activity in SCLC with fewer diarrhea, and which evaluated pts’ QOL twice: at the baseline and after comple...
6